´º½º |
IT »ê¾÷¿¡¼ÀÇ ÁöÀûÀç»ê±Ç ³²¿ë°ú °úÁ¦- °í·Á´ëÇб³ ICR¼¾ÅÍ ÁÖÃÖ ¼¼¹Ì³ª °³ÃÖ ¹é°æÈñ |
|
°í·Á´ëÇб³ Çõ½Å¡¤°æÀ±ÔÁ¦¹ý¼¾ÅÍ(ICR¼¾ÅÍ, ¼ÒÀå À¯ÁøÈñ)´Â 2ÀÏ ¼¿ï ¿ª»ïµ¿ Çѱ¹Áö½ÄÀç»ê¼¾ÅÍ ±¹Á¦È¸Àǽǿ¡¼ Á¤ºÎ ¹× ±¹³»¿Ü ¹ýÇÐÀÚ, ¹ý¹«¹ýÀΰú ±â¾÷ÀεéÀÌ ÇÔ²² Âü¿©ÇÑ °¡¿îµ¥ 'IT »ê¾÷¿¡¼ ÁöÀûÀç»ê±Ç ¶óÀ̼¾½ÌÀÇ Á¦ ¹®Á¦'¸¦ ÁÖÁ¦·Î ÁöÀûÀç»ê±ÇÀÇ ¹ýÀû ±ÔÁ¦ ¿¬±¸ ¼¼¹Ì³ª¸¦ °³ÃÖÇÑ´Ù.
Áö³ 3¿ùÀÇ ¼ÒÇÁÆ®¿þ¾î»ê¾÷, 4¿ùÀÇ IT»ê¾÷ ºÐ¾ß¿¡ ÀÌ¾î ¼¼ ¹øÂ°ÀÎ 5¿ù¿¡´Â ÃÖ±Ù Á߿伺ÀÌ ºÎ°¢µÇ°í ÀÖ´Â Á¦¾à»ê¾÷ ºÐ¾ß¿¡¼ Reverse Payment ¹× ƯÇ㠱Ⱓ¿¬Àå µîÀ» Áß½ÉÀ¸·Î ´Ù·é´Ù. ƯÈ÷ À̹ø ¼¼¹Ì³ª´Â Çѱ¹¿¬±¸Àç´ÜÀÌ »çȸ°úÇÐÀÇ Åë¼·Àû ¹ßÀüÀ» Áö¿øÇϱâ À§ÇØ ½Ç½ÃÇÏ´Â Social Science Korea »ç¾÷ÀÇ ¡¸¹ý°ú °æÁ¦¡¹ ¿¬±¸ÆÀ°ú °øµ¿ ÁÖÃÖÇÏ¿© ´õ¿í Àǹ̰¡ ÀÖ´Ù.
ÀÌ ³¯ÀÇ ¼¼¹Ì³ª Á¦1ºÎ¿¡¼´Â ¹Ì±¹ Federal Trade CommissionÀÇ Assistant DirectorÀÎ ¸¶Ä¿½º ¸ÞÀ̾î(Markus Meier)ÀÇ 'U.S. Federal Trade Commission Briefing on Pharmaceutical'Pay-for-Delay' Settlements'¸¦ ½ÃÀÛÀ¸·Î, ³²ÀçÇö °í·Á´ë °æÁ¦Çаú ±³¼ö°¡ 'ƯÇãºÐÀï ÈÇØÀÇ °æÁ¦ÇÐÀû ºÐ¼®'À», ¸¶Å° Äí´Ï¸¶Ã÷(Maki Kunimatsu) ÀϺ» Ãò¿À´ë(ñéäçÓÞ) °æ¿µ´ëÇпø ±³¼ö°¡ 'Pharmaceutical Industry, IPR Licensing and Antitrust Regulations in Japan'À» ÁÖÁ¦ ¹ßÇ¥ ÇÑ´Ù.
Á¦ 2ºÎ¿¡¼´Â ±èÁØÇÏ °úÀå(°øÁ¤°Å·¡À§¿øÈ¸)ÀÇ 'Á¦¾à»ê¾÷¿¡¼ÀÇ IPR Licensing¿¡ ´ëÇÑ °øÁ¤À§¹ýÁýÇà ¹æÇâ'¿¡ À̾î, À̼®ÁØ º¯È£»ç(¹ý¹«¹ýÀÎ À²ÃÌ)°¡ 'Reverse PaymentAgreement¿¡ ´ëÇÑ °æÀï¹ýÀû ±ÔÁ¦'¿¡ ´ëÇØ ÁÖÁ¦¹ßÇ¥¸¦ ÇÒ ¿¹Á¤ÀÌ´Ù.
ÁÖÁ¦¹ßÇ¥°¡ ³¡³ ÈÄ¿¡´Â ½ÇÁ¦ ÇöÀå¿¡¼ °ü·Ã ¾÷¹«¸¦ ´ã´çÇϰí ÀÖ´Â Çаè, °øÁ¤°Å·¡À§¿øÈ¸, ƯÇãû, ±¹³»¿Ü ±â¾÷°ú ·ÎÆß µî ÃÖ°íÀÇ Àü¹®°¡µéÀÌ ÇöÇà ÁöÀûÀç»ê±Ç °ü·Ã ¹ýÁ¦ÀÇ ¹®Á¦Á¡ ¹× °³¼±¹æ¾ÈÀ» Åä·ÐÇÏ´Â ¼ø¼·Î ¸¶·ÃµÇ¾ú´Ù. ƯÈ÷ À̹ø ¼¼¹Ì³ª´Â ±è¾ØÀå ¹ý·ü»ç¹«¼Ò, ¹ý¹«¹ýÀÎ ±¤Àå, ¼¼Á¾, À²ÃÌ µî ´ëÇü ·ÎÆßµéÀÌ °øµ¿À¸·Î ÈÄ¿øÇÏ°í ¹ßÇ¥Áø¿¡ Âü¿©ÇÏ´Â ÇÑÆí, °øÁ¤°Å·¡À§¿øÈ¸¿Í ƯÇãû ¹× ±â¾÷µéµµ Åä·Ð¿¡ ³ª¼³ ¿¹Á¤ÀÌ´Ù.
< ÀúÀÛ±ÇÀÚ © ȯ°æ¹ý·ü½Å¹® ¹«´ÜÀüÀç ¹× Àç¹èÆ÷±ÝÁö > |
|
|
|
|
ÀÌ ±â»ç¿¡ ´ëÇÑ ´ñ±Û À̾߱â (0) |
|
|
|